Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR011 in Relapsed/Refractory B-cell NHL
NCT03299738Phase 1Unknown
- Sponsor
- AbelZeta
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C-CAR011 in B-cell non-Hodgkin lymphoma, sponsored by AbelZeta. Primary endpoints: Safety (Vital signs, physical examination, clinical laboratory tests, incidence of AEs and SAEs) at 12 weeks and Overall Response Rate at 12 weeks. Status: unknown.
02
Drugs
C-CAR011
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03299738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03299738.